Evaluating prescribing and access trends for adalimumab biosimilars in pediatric and adolescent care
Authors:
- 5 May 2026
- journal article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 83 (21) , e821-e829
Abstract
Purpose: The expiration of market exclusivity for Humira (adalimumab) in February 2023 led to the introduction of 10 biosimilars, raising questions about their impact on prescribing trends, payer responses, and formulary management in pediatrics. The primary objective of this study was to compare time to prior authorization approval between adalimumab biosimilars and the originator product during the first 2.5 years following biosimilar market entry. Secondary objectives were to describe the reason for switching adalimumab products in those already established on adalimumab therapy and to identify reported intolerances associated with biosimilar products. Methods: To prepare for biosimilar launches, the clinical pharmacy team provided education to clinic staff and the health-system specialty pharmacy (HSSP), engaged with manufacturers to identify resources related to biosimilar products, and established prescribing workflows for patients on adalimumab. An observational study was then conducted from February 1, 2023, to June 30, 2025, across dermatology, gastroenterology, and rheumatology outpatient clinics of an integrated HSSP to assess biosimilar prescribing trends, time to authorization approval, and reason for switches. Included prescriptions were for patients naïve to adalimumab or switching between adalimumab products. Results: Evaluation of 350 prescriptions for adalimumab-naïve patients found that Humira was the preferred product for 290 prescriptions (82.9%). In adalimumab-naïve patients, the median time to prior authorization approval was 4 days (interquartile range [IQR], 2-9 days), with no significant difference between Humira (4 days; IQR, 2-10 days) and biosimilars (3 days; IQR, 2-9 days; P = 0.39). Among 256 prescriptions for non–adalimumab-naïve patients, the majority (86%) were for switches from Humira to a biosimilar, primarily due to formulary preference (77%), new insurance for the patient (11.3%), or exhaustion of copay card funds (4.7%). Conclusion: Despite inherent complexities of biosimilar implementation, this study demonstrates that a coordinated, pharmacist-led approach supports timely access to therapy and minimizes treatment delays.Keywords
This publication has 13 references indexed in Scilit:
- Use, Spending, and Prices of Adalimumab Following Biosimilar CompetitionJAMA Health Forum, 2024
- Primary care team member’s perceptions of credentialed and privileged clinic pharmacists and impact on clinic workload in a pediatric primary care networkJournal of the American Pharmacists Association, 2024
- Patent Portfolios Protecting 10 Top-Selling Prescription DrugsJAMA Internal Medicine, 2024
- INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRYInflammatory Bowel Diseases, 2024
- Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacistsAmerican Journal of Health-System Pharmacy, 2023
- Evaluation of a remote hybrid staffing model for ambulatory clinical pharmacists in a pediatric health system during the COVID-19 pandemicAmerican Journal of Health-System Pharmacy, 2022
- There Is No Substitute for Effective Education About BiosimilarsCrohn's & Colitis 360, 2021
- Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the MoneyInflammatory Bowel Diseases, 2021
- Biosimilar medicines uptake: The role of the clinical pharmacistExploratory Research in Clinical and Social Pharmacy, 2021
- Credentialing and privileging for clinical pharmacistsJACCP: Journal of the American College of Clinical Pharmacy, 2019